| Popis: |
Pedro Santos-Moreno,1 Susan Martinez,2 Linda Ibatá,2 Laura Villarreal,1 Manuel Rivero,3 Adriana Rojas-Villarraga4 1Rheumatology, Biomab IPS, Bogotá, DC, Colombia; 2Epidemiology, Biomab IPS, Bogotá, DC, Colombia; 3Pharmacy, Biomab IPS, Bogotá, DC, Colombia; 4Rheumatology, Research División, Fundación Universitaria de Ciencias de la Salud – FUCS, Bogotá, DC, ColombiaCorrespondence: Pedro Santos-MorenoRheumatology, Biomab IPS, Calle 48 # 13-86, Bogotá, ColombiaEmail pedrosantosmoreno@hotmail.comObjective: Although it is known that methotrexate (MTX) increases the effectiveness of biological drugs (mainly anti-TNFs) in patients with rheumatoid arthritis (RA), in real life, it is known that many patients using anti-TNFs are on monotherapy due to many causes. This article compares the effectiveness of certolizumab as monotherapy as combined with MTX or leflunomide (LFN) in RA patients with failure to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in a real-world setting.Methods: A retrospective observational cohort study was conducted at a specialized centre for RA management in Colombia. Patients treated with certolizumab as monotherapy or in combination with MTX, LFN, or MTX+LFN, between 2011 and 2020 with a minimum 3-month follow-up were included. Demographics and RA clinical characteristics were recorded; effectiveness was assessed as the improvement in Disease Activity Score (DAS28) getting remission or low disease activity at 3, 6, and 12 months of treatment.Results: A total of 181 patients were included, 24 received certolizumab as monotherapy, 62 certolizumab plus MTX, 47 certolizumab plus LFN and 48 certolizumab plus MTX+LFN. At 3 months of follow-up, 80% of the patients showed decreased disease activity, with no significant differences between groups; at 12 months of treatment, response in certolizumab monotherapy group was 94.4% compared to 81.8% in combination with MTX, 80.5% in combination with LFN and 51.4% in combination with MTX+LFN. Response at 3 months (OR 4.04; 95% CI 1.28– 12.69) and positive anti-CCP (OR 3.83; 95% CI 1.11– 13.21) were associated with 12-month response.Conclusion: Certolizumab seems to be effective as monotherapy in the treatment of RA patients with failure to csDMARDs.Keywords: rheumatoid arthritis, treatment, anti-TNFs, certolizumab, monotherapy |
